CHD5 methylation has been identified in several cancer types including glioma, breast, colon, lung, ovary and prostate cancers [18, 22], suggesting the contribution of epigenetic regulation to its biallelic inactivation [18]. This evidence concerns the gene CHD5 and glioma.